Duodenal GISTs are sometimes difficult to define anatomically and surgical resection may prove challenging.
Small intestinal GIST and intussusception is an exceedingly rare occurrence and can be difficult to diagnose.
To improve adherence to treatment regimens prescribed, we first need to understand the underlying concerns of patients.
There are a few major hurdles physicians have to navigate when treating pediatric patients with gastrointestinal stromal tumors.
Artificial intelligence has been shown to have good predictive value for the malignant potential of gastrointestinal stromal tumors.
Recently developed TKIs such as ripretinib and avapritinib have the potential to change the treatment landscape of GIST.
Various studies have analyzed how to better diagnose gastrointestinal stromal tumors at the preoperative stage.
We explore how imatinib became the first-line therapy for metastatic GIST, and whether it should be discontinued in some circumstances.
We discuss current therapeutic strategies in targeting the PDGF/PDGFR signaling pathway in cancer research.